BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors. 2010

Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China.

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in the process of cancer angiogenesis. A series of quinoline amide derivatives were prepared and found to be good inhibitors of VEGFR-2. The inhibitory activities were investigated against VEGFR-2 kinase and human umbilical vein endothelial cells (HUVEC) in vitro. Compound 6 (5-chloro-2-hydroxy-N-(quinolin-8-yl)benzamide) exhibited the most potent inhibitory activity (IC(50)=3.8 and 5.5 nM for VEGFR-2 kinase and HUVEC, respectively). Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of VEGFR-2, which demonstrates that compound 6 is a potential agent for cancer therapy deserving further researching.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011804 Quinolines
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory
D040301 Vascular Endothelial Growth Factor Receptor-2 A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF. VEGFR-2,Fetal Liver Kinase-1,Flk-1 Protein,Flk-1 Receptor Tyrosine Kinase,KDR Tyrosine Kinase,Kinase Insert Domain Receptor,VEGF Receptor Flk-1,VEGF Receptor KDR,Fetal Liver Kinase 1,Flk 1 Protein,Flk 1 Receptor Tyrosine Kinase,Flk-1, VEGF Receptor,KDR, VEGF Receptor,Tyrosine Kinase, KDR,VEGF Receptor Flk 1,Vascular Endothelial Growth Factor Receptor 2

Related Publications

Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, Synthesis and Biological Evaluation of Uracil Derivatives as Novel VEGFR-2 Inhibitors.
January 2018, Current pharmaceutical design,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors.
September 2019, Bioorganic & medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation.
January 2014, Bioorganic & medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
February 2017, Bioorganic & medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
August 2018, Bioorganic chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
November 2019, European journal of medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
January 2018, Archiv der Pharmazie,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
October 2015, Bioorganic & medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
June 2015, European journal of medicinal chemistry,
Ying Yang, and Lei Shi, and Yang Zhou, and Huan-Qiu Li, and Zhen-Wei Zhu, and Hai-Liang Zhu
Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
March 2009, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!